POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV

POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV

Bibliographic Details
Main Authors: D. Cherney, B. Charbonnel, F. Cosentino, R.E. Pratley, S. Dagogo-Jack, W.J. Shih, D.K. McGuire, R. Frederich, M. Maldonado, J. Liu, A. Pong, C. Liu, C.P. Cannon
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024921005179
id doaj-3ab782ab6b4c49498b160aec295be5c2
record_format Article
spelling doaj-3ab782ab6b4c49498b160aec295be5c22021-04-18T06:30:07ZengElsevierKidney International Reports2468-02492021-04-0164S154S155POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CVD. Cherney0B. Charbonnel1F. Cosentino2R.E. Pratley3S. Dagogo-Jack4W.J. Shih5D.K. McGuire6R. Frederich7M. Maldonado8J. Liu9A. Pong10C. Liu11C.P. Cannon12Toronto General Hospital, Division of Nephrology, Toronto, CanadaUniversity of Nantes, Department of Endocrinology and Diabetes, Nantes, FranceKarolinska Institute and Karolinska University Hospital, Unit of Cardiology, Stockholm, SwedenAdventHealth Translational Research Institute, Diabetes Institute, Orlando, United StatesUniversity of Tennessee Health Science Center, Division of Endocrinology and Diabetes and Metabolism, Memphis, United StatesRutgers School of Public Health and Rutgers Cancer Institute of New Jersey, Department of Biostatistics and Epidemiology, New Brunswick, United StatesUniversity of Texas Southwestern Medical Center & Parkland Health and Hospital System, Division of Cardiology, Dallas, United StatesPfizer Inc., Research and Development, Collegeville, United StatesMerck Sharp & Dohme Limited, Diabetes and Endocrinology, London, United KingdomMerck & Co. Inc., Clinical Research, Kenilworth, United StatesMerck & Co. Inc., Biostatistics, Kenilworth, United StatesMerck & Co. Inc., Biostatistics, Kenilworth, United StatesHarvard Medical School, Cardiovascular Division, Boston, United Stateshttp://www.sciencedirect.com/science/article/pii/S2468024921005179
collection DOAJ
language English
format Article
sources DOAJ
author D. Cherney
B. Charbonnel
F. Cosentino
R.E. Pratley
S. Dagogo-Jack
W.J. Shih
D.K. McGuire
R. Frederich
M. Maldonado
J. Liu
A. Pong
C. Liu
C.P. Cannon
spellingShingle D. Cherney
B. Charbonnel
F. Cosentino
R.E. Pratley
S. Dagogo-Jack
W.J. Shih
D.K. McGuire
R. Frederich
M. Maldonado
J. Liu
A. Pong
C. Liu
C.P. Cannon
POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV
Kidney International Reports
author_facet D. Cherney
B. Charbonnel
F. Cosentino
R.E. Pratley
S. Dagogo-Jack
W.J. Shih
D.K. McGuire
R. Frederich
M. Maldonado
J. Liu
A. Pong
C. Liu
C.P. Cannon
author_sort D. Cherney
title POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV
title_short POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV
title_full POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV
title_fullStr POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV
title_full_unstemmed POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV
title_sort pos-354 worsening kidney disease influences the efficacy of ertugliflozin on glucosuria-mediated endpoints but does not influence the efficacy on natriuresis-related endpoints: prespecified analyses from vertis cv
publisher Elsevier
series Kidney International Reports
issn 2468-0249
publishDate 2021-04-01
url http://www.sciencedirect.com/science/article/pii/S2468024921005179
work_keys_str_mv AT dcherney pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT bcharbonnel pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT fcosentino pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT repratley pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT sdagogojack pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT wjshih pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT dkmcguire pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT rfrederich pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT mmaldonado pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT jliu pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT apong pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT cliu pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
AT cpcannon pos354worseningkidneydiseaseinfluencestheefficacyofertugliflozinonglucosuriamediatedendpointsbutdoesnotinfluencetheefficacyonnatriuresisrelatedendpointsprespecifiedanalysesfromvertiscv
_version_ 1721523271404355584

Similar Items